Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,
It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.
Clopidogrel was granted FDA approval on 17 November 1997.
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
- Associated Therapies
- -
An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease
- Conditions
- Interventions
- First Posted Date
- 2010-05-06
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 146
- Registration Number
- NCT01118325
- Locations
- 🇵🇭
Research Site, Quezon City, Philippines
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
- Conditions
- Interventions
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2012-11-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 282
- Registration Number
- NCT01115738
- Locations
- 🇮🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Delhi, India
Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor - Optimize Trial
- First Posted Date
- 2010-04-29
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- Cardiovascular Research Center, Brazil
- Target Recruit Count
- 3119
- Registration Number
- NCT01113372
- Locations
- 🇧🇷
Hospital Anchieta, Brasília, DF, Brazil
🇧🇷Universidade Federal do Triangulo Mineiro, Uberaba, MG, Brazil
🇧🇷Instituto do Coração do Triângulo Mineiro, Uberlândia, MG, Brazil
Effects of Clopidogrel on Blood Pressure
- Conditions
- Interventions
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2010-04-28
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 46
- Registration Number
- NCT01112137
- Locations
- 🇩🇪
University of Cologne, Cologne, Germany
🇳🇱St Antonius Hospital Nieuwegein, Nieuwegein, Netherlands
Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).
- Conditions
- Interventions
- First Posted Date
- 2010-04-23
- Last Posted Date
- 2010-08-24
- Lead Sponsor
- University of Patras
- Target Recruit Count
- 70
- Registration Number
- NCT01109784
- Locations
- 🇬🇷
Cardiology Department, Patras University Hospital, Rio, Patras, Greece
Reproducibility and Comparison of Platelet Function Assays With Aspirin and Clopidogrel (MK-0000-167)
- Conditions
- Interventions
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15
- Registration Number
- NCT01108588
Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease
- First Posted Date
- 2010-04-21
- Last Posted Date
- 2012-10-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 155
- Registration Number
- NCT01107912
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden
Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease
- First Posted Date
- 2010-04-21
- Last Posted Date
- 2012-08-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT01107925
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden
Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes
- First Posted Date
- 2010-04-21
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 29
- Registration Number
- NCT01107899
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany
Clopidogrel/Aspirin Interaction Study
- First Posted Date
- 2010-04-13
- Last Posted Date
- 2015-04-28
- Lead Sponsor
- Population Health Research Institute
- Target Recruit Count
- 82
- Registration Number
- NCT01102439
- Locations
- 🇨🇦
Population Health Research Institute, Hamilton, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.